September 26, 2021
  • September 26, 2021
  • Home
  • Eye diseases
  • Aerie Pharmaceuticals Announces Presentation at Ophthalmology Innovation Summit European Innovation Showcase

Aerie Pharmaceuticals Announces Presentation at Ophthalmology Innovation Summit European Innovation Showcase

By on July 20, 2021 0

DURHAM, NC – (COMMERCIAL THREAD) – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-class therapies for the treatment of patients with open-angle glaucoma, surface diseases eye and retinal diseases, today announced that David A. Hollander, MD, MBA, Director of Research and Development, presented an overview of Aerie’s globalization outlook at the Ophthalmology Innovation Summit European Innovation Showcase. The slide presentation includes an overview of Aerie’s approach in Europe for its glaucoma franchise and Aerie’s product candidates.

Today’s event slide show is available now and can be viewed by visiting Aerie’s website at http://investors.aeriepharma.com.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and diseases of the retina. Aerie’s first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drops approved by the United States Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma. open angle or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal whorls, instillation site pain and conjunctival hemorrhage. More information on Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02% / 0.005%, the first and only fixed-dose combination of Rhopressa® and the widely prescribed latanoprost PGA (prostaglandin analogue), was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal whorls, instillation site pain and conjunctival hemorrhage. More information on Rocklatan®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including age-related wet macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.


Source link